BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, a commercial-stage biopharmaceutical company, today announced that the Phase III clinical trial comparing the safety and efficacy of BAT1706 versus Avastin® 1 (bevacizumab) met its primary endpoint. BAT1706 is being developed by Bio-Thera So...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, today announced that QLETLI ® (格乐立 ® ), a biosimilar to Humira ® (adalimumab), is now available in China. QLETLI ® (格乐立 ® ), the first adalimumab biosimilar approved by the Chi...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate a Phase I clinical study to compare the phar...
